Symposium
THe LAW AND ECONOMICS of DRUG DEVELOPMeNt
|
November 7, 2008
University of Michigan Law School,
Hutchins Hall, Room 250
Ann Arbor, Michigan
Free and open to the public
Registration Page
|
New drugs promise to prolong and improve the quality of human lives. But, as the cost of new drug development increases, policy makers face difficult tradeoffs. This symposium will address some of the most pressing policy questions facing FDA, Congress, and the courts, including:
- How have recent regulatory initiatives affected the introduction of new drugs?
- What role remains for state tort liability alongside the federal regime for regulating the safety of drugs?
- How can the current system of incentives be improved?
|
Participants in the Conference include: Robert Armitage (Eli Lilly Corp.), Omri Ben-Shahar (Chicago), Rebecca Eisenberg (Michigan), Scott Hemphill (Columbia), Peter Barton Hutt (Covington & Burling LLP), Ariel Katz (Toronto), Frank Lichtenberg (Columbia), Lars Noah (Florida), Mary Olson (Tulane), Ben Roin (Harvard), Catherine Sharkey (NYU), Scott Stern (Northwestern), Qing Zhang (China Univ. of Pol. Sci. & Law).
Sponsored by the Program in Law, Economics, & Technology and Michigan Telecommunications & Technology Law Review, with generous funding from Microsoft Corporation.
Program
|
8:30 |
Continental Breakfast |
|
9:15-9:30 |
Welcome Remarks - Rebecca Eisenberg |
|
9:30-12:00 |
Panel on Regulatory Initiatives (Omri Ben-Shahar, Moderator)
Ariel Katz
Frank Lichtenberg
Mary Olson
Scott Stern
Qing Zhang |
|
12:00-1:00 |
Lunch Break |
|
1:00-1:15 |
Remarks (Afternoon Session) |
|
1:15-3:30 |
Panel on Alternative Perspectives on IP Regimes (Peter Barton Hutt, Moderator)
Robert Armitage
Rebecca Eisenberg
Scott Hemphill
Ben Roin |
|
3:30-3:45 |
Coffee Break |
|
3:45-4:45 |
Panel on Federal Preemption and Torts (Rebecca Eisenberg, Moderator)
Lars Noah
Catherine Sharkey |
|
4:45-5:00 |
Closing Remarks |